Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Through this process, fresher and brighter skin emerges with reduced melanin content
March 19, 2026: Eli Lilly announced TRANSCEND-T2D-1 topline results in adults with type 2 diabetes
Survodutide Timeline Boehringer Ingelheims SYNCHRONIZE program includes multiple Phase 3 trials: SYNCHRONIZE-1: Obesity without type 2 diabetes (726 participants, 76 weeks) SYNCHRONIZE-2: Obesity with type 2 diabetes (755 participants, 76 weeks) SYNCHRONIZE-CVOT: Cardiovascular outcomes (4,935 participants target) LIVERAGE trials: MASH-specific studies initiated October 2024 FDA Breakthrough Therapy designation for MASH may accelerate review for that indication specifically
The GLP-1 consumer changes the brief in at least three meaningful ways
US$ 21.06
US$ 20.72
US$ 25.02
US$ 20.61
US$ 27.04
